Calciphylaxis is a rare, life-threatening skin disorder characterized by cutaneous arteriolar calcification with subsequent tissue ischemia and infarction that is followed by intense painful deep ulcerations associated with substantial morbidity and mortality.1 It is mainly observed in dialysis, near-dialysis, or the kidney transplant population, with an estimated incidence of 1% to 4%, but can also occur in patients without kidney impairment (nonuremic calciphylaxis).2 The high index of morbidity is predominantly because of the severe pain from the ulcer, slow or nonhealing wounds, frequent hospitalizations, and infection. The reported annual mortality rate is at 45% to 80% in patients receiving dialysis.3